The ASX requirements for continuous disclosure obligations for biotech companies, are a little different, and make provision for such an abstract to be presented first..... at a conference, such as next weekend. Prior to acceptance of the data and information, indeed SNO peer review its content, and authorize investigator abstract presentation, at the 4 day conference.
Update prior to trading Monday, before market opens. I think the company has done everything in accordance with the norm and ASX guidelines for this sector.
"The Code recognises the importance of peer review in the validation process and acknowledges that in some circumstances disclosure of results before peer review (through publication in a medical journal, presentation at a scientific meeting or otherwise) may be premature."
CHM Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)